Clinical Trial Update: A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation trial of an SHP2 inhibitor in patients with solid tumors harboring KRAS or EGFR mutations is currently active and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• SHP2 inhibitor

Snippet

Sponsor: HUYABIO International, LLC. | Conditions: Non Small Cell Lung Cancer, Colorectal Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING